Shares of Cardinal Health surged 6.7% to $279.45 on November 5 after the company posted fiscal first-quarter results that cleared Wall Street's bar and prompted management to lift its profit forecast for the full year — a one-two punch that raises a pointed question about how much growth investors can realistically expect from a business built on razor-thin margins. Cardinal Health Clears a High Bar With Blowout Earnings and a Raised Outlook — But How Much Good News Is Already Baked Into the Stock?
Shares jumped 6.7% to $279.45 Thursday morning after Cardinal Health delivered a fiscal first quarter that beat expectations on every line that matters and lifted its full-year profit forecast. The stock has now climbed 27% since the beginning of the year, roughly double the S&P 500's gain — an unusual run for a company whose core job is moving boxes of pills from manufacturers to pharmacies. The question for investors: does the price already reflect a perfect year?
A $0.32 Earnings Beat Signals More Than Luck. Cardinal posted non-GAAP earnings of $3.26 per share, beating the consensus estimate by $0.32 . That extends a streak of four consecutive quarters of topping EPS expectations . Pharmaceutical segment profit grew 17% on just 6% revenue growth, showing the company is squeezing more profit from each dollar of drug sales . In a business where gross margins hover around low single digits, that kind of operating leverage — earning more without proportionally more revenue — matters enormously.
A Bigger Annual Forecast Resets the Math. Management raised full-year EPS guidance to $12.80–$13.00, up from $12.40–$12.60 . That translates to 17%–19% growth over the adjusted fiscal 2026 baseline . At the midpoint of the new range and today's price, Cardinal trades at roughly 21.7x forward earnings — a rich tag for a distributor that historically fetched mid-teens valuations. Investors are betting the profit trajectory is durable, not a one-quarter blip.
The CVS Contract Removes a Major Risk. In October, Cardinal signed a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 2032 . The deal removed a key overhang — Wall Street's fear that CVS could renegotiate on punishing terms or shift volume . CVS is a critical customer, and the renewal adds years of revenue visibility .
Buybacks Are Doing Heavy Lifting. Cardinal completed a $500 million accelerated share repurchase program in Q1, shrinking the share count and boosting per-share earnings growth to 28% year-over-year . That is a tailwind, but one that requires cash. With consolidated gross profit up 12% to $2.6 billion , the company can fund buybacks today — though any margin pressure would force a harder choice between returning cash and investing in growth.
Bottom line: Cardinal Health is executing cleanly, but at nearly 22x earnings, the stock price assumes continued flawless delivery. Any stumble in specialty pharma growth or medical-segment margins could reset expectations fast.